SRPT Talking w/ More Than a Dozen Drug Makers on Partnership. /////// POST
Duchenne Muscular Dystrophy Drug Could Unlock Huge Potential For This Pharmaceutical
By Jordo Bivona - January 31, 2013
Sarepta may seek advisers to find an overseas partner for the therapy. The company is talking with more than a dozen drug makers about a partnership for international sales of eteplirsen. While successful testing of eteplirsen may make Sarepta an acquisition target, CEO Christopher Garabedian said he wants it to become a rival to large biotechnology companies such as Gilead
Sciences (NASDAQ: GILD), the world’s biggest maker of AIDS medicines, and Celgene (NASDAQ: CELG), the maker of the $3 billion cancer drug Revlimid.